Premium
Sleeve lobectomy versus lobectomy for primary treatment of non‐small–cell lung cancer: A single‐center retrospective analysis
Author(s) -
Zalepugas Donatas,
Koryllos Aris,
Stoelben Erich,
Ludwig Corinna
Publication year - 2021
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.26286
Subject(s) - medicine , perioperative , surgery , lung cancer , pneumonectomy , retrospective cohort study , survival rate , single center
Background and Objectives It is unclear how much additional perioperative risk a sleeve lobectomy could pose in comparison to lobectomy. The objective of this analysis was to compare the complication rate, 30‐day mortality, and overall survival between lobectomy and sleeve lobectomy without prior neoadjuvant treatment in non‐small–cell lung cancer (NSCLC). Methods This is a retrospective study using our prospective database for quality assurance in our hospital. Inclusion criteria for our study was a completed lobectomy or sleeve lobectomy for primary treatment of NSCLC. Results In 506 patients, the tumor was treated by means of standard lobectomy. In 252 patients with central tumor localization, sleeve lobectomy was performed. Postoperative complications occurred in n:148 (29.24%) patients of the lobectomy group and in n = 76 (30.15%) of the sleeve group. The mortality rate difference between the two groups was statistically significant and favored the lobectomy group (0.78% vs. 4.76%, p = .007). Five year survival was 69.97% for the lobectomy and 65.59% for the sleeve group ( p = .829). Conclusion Sleeve lobectomy for primary surgical treatment of NSCLC has comparable perioperative complications with lobectomy. Sleeve lobectomy does not seem to negatively influence survival. Postoperative mortality was higher in the sleeve group.